ZIVO Reports Favorable Results from 42-Day Confirmatory Study of its Coccidiosis Treatment in Broiler Chickens

ZIVO Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, reports favorable results from its latest 42-day study with its product targeting coccidiosis in broiler chickens.

The study, which was conducted in collaboration with a major global animal health company and replicated real-world poultry production environments, further validates the efficacy of ZIVO’s non-antibiotic, immune-modulating product designed for the treatment of coccidiosis. Funded by the major animal health company, the study focused on the overall health and productivity of birds challenged with the coccidiosis-causing parasite, Eimeria, while comparing administration of ZIVO’s product alone or in combination with either an ionophore-based treatment or a coccidiosis vaccine versus birds treated with the ionophore or vaccination alone. Uninfected/untreated healthy birds and infected/untreated birds served as negative and positive disease controls, respectively.

In this study, broiler chickens infected with coccidiosis and treated with ZIVO’s product in combination with an anticoccidial ionophore or vaccination exhibited statistically significant improvements in both growth performance (as measured by feed conversion ratio, FCR) and clinical signs of disease (as measured by intestinal lesion scores), compared with chickens that received only the ionophore or vaccine. With respect to FCR over the 42-day grow-out period, groups treated with ZIVO’s product in combination with either the ionophore or vaccination performed on par with the healthy, uninfected control group.

“We are delighted to report favorable findings from this new study that confirm the effectiveness of our product to support poultry health and productivity in the presence of coccidiosis. These results further demonstrate the versatility of our product candidate not only because of its ability to enhance currently available treatment options, but also because of its standalone treatment potential as validated in numerous prior studies. Maintaining feed conversion ratios comparable to uninfected birds is a notable finding that underscores the value our product offers the poultry industry,” said John Payne, Chairman and CEO of ZIVO Bioscience.

“Coccidiosis is one of the most challenging and costly diseases in poultry production, and the ability to improve outcomes using our product in combination with existing interventions represents a potential breakthrough in disease management. We look forward to advancing our discussions global animal health companies in preparation for commercial markets,” he added.

About Coccidiosis

Coccidiosis is a protozoal disease that causes diarrhea, weight loss, decreased performance and increased mortality in poultry. This disease represents a significant economic challenge for the global poultry industry, and as indicated by a 2020 study, the estimated annual costs are approximately $14 billionⁱ. Products for treating coccidiosis are mostly antibiotic- or ionophore-based, and no significant new commercial technology has been introduced in the past 60 years. The global poultry industry spends more than $1.5 billion annually on coccidiosis control, primarily using decades-old compounds that industry and consumers alike want to replace due to the risks of developing drug resistance. Coccidiosis is a common disease for chickens, especially among young chicks, and can be fatal or result in compromised digestion.

About ZIVO Bioscience

ZIVO Bioscience is a research and development company with an intellectual property portfolio comprised of proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques and patented or patent pending inventions for applications in human and animal health. Please visit www.zivobioscience.com for more information.

Forward Looking Statements

Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including with respect to the Company’s product candidate’s potential to generate revenues and the expected time frame for results of future studies. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. Although ZIVO believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks that our strategic partnerships may not facilitate the commercialization or market acceptance of our products; risks that we will be unable to increase production sufficient to meet our expected demand; risks that our products may not be ready for commercialization in a timely manner or at all; risks that our products will not perform as expected based on results of our pre-clinical and clinical trials; our ability to raise additional funds; uncertainties inherent in the development process of our products; changes in regulatory requirements or decisions of regulatory authorities; the size and growth potential of the markets for our products; the results of clinical trials, our ability to protect our intellectual property rights and other risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and ZIVO undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.

_________________________

ⁱ Blake, D.P., Knox, J., Dehaeck, B. et al. Re-calculating the cost of coccidiosis in chickens. Vet Res 51, 115 (2020). https://doi.org/10.1186/s13567-020-00837-2

View source version on businesswire.com: https://www.businesswire.com/news/home/20240823637788/en/